Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer

• Status: Terminated
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to investigate if treatment with zalutumumab in combination with chemotherapy and radiotherapy (chemo-radiation) will lead to a prolonged life in patients with lung cancer compared to patients treated with chemo-radiation alone.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Genmab
• Treatments: Antibodies, Monoclonal; Zalutumumab

Criteria

Inclusion Criteria:

• NSCLC stage IIIA-IIIB

• Performance status 0 or 1 (Zubrod or WHO Scale)

Exclusion Criteria:

• Evidence of metastases either in a separate lobe of the lung, or extra thoracic

• Patients with high risk of radiation pneumonitis and or compromised lung function

• Estimated life expectancy of less than 3 months

• Prior chemotherapy for lung cancer

• Prior radiotherapy to the chest

• Prior surgery with curative intent for lung cancer